摘要
目的:用16α-18F-17β-雌二醇(18F-FES)小动物PET/CT评价不同类型乳腺癌模型雌激素受体(ER)表达的差异。方法:用ER阳性人乳腺癌细胞(ZR-75-1、MCF-7)和阴性细胞(MDA-MB-231)构建荷瘤裸鼠动物模型。阳性组每组各10只,接种前3 d植入雌激素缓释片,再将细胞与基质胶混合液接种于乳腺脂肪垫,成瘤后显像前3 d取出缓释片。阴性组5只,直接将细胞悬液接种于乳腺脂肪垫。当肿瘤长至长径5 mm左右时行18F-FES PET/CT显像,用%ID/gmax定量ER表达,然后用免疫组化测定并比较ER结果。数据分析采用单因素方差分析。结果:ZR-75-1、MCF-7和MDA-MB-231的瘤体成瘤率分别为100%(10/10)、70%(7/10)和100%(5/5),瘤体随时间延长而增大,但三组之间差异无统计学意义(P>0.05),18F-FES%ID/gmax分别为6.6±1.0、3.3±0.5和1.1±0.1,三组之间差异均有统计学意义(P<0.05)。T/M比值分别为4.2±0.3、2.6±0.2和1.1±0.1,三组之间差异均有显著统计学意义(P<0.001)。18F-FES显像结果与免疫组化结果呈正相关(%ID/gmax:r2=0.65,P<0.001;T/M:r2=0.87,P<0.001)。结论:18F-FES PET/CT的%ID/gmax能准确评价不同类型荷人乳腺癌模型的ER表达水平,从而为进一步研究乳腺癌内分泌疗效提供了一种活体、无创、动态的分析方法。
Objective： To evaluate estrogen receptor （ER） expression level in human breast cancer model using 18F-lfuoroestradiol （18F-FES） microPET/CT. Methods：ER＋human breast cancer cell lines （ZR-75-1 and MCF-7） and ER-control （MDA-MB-231） were used to construct BALB/c nude mouse model. There were ten mice in each ER＋group. The estrogen pellets were implanted 3 d prior to tumor cell inoculation and removed 3 d before administration of 18F-FES. The mice were implanted with ZR-75-1 and MCF-7. There were 5 mice in ER-group. MDA-MB-231 cells were inoculated into thoracic mammary fat pad. 18F-FES PET/CT was performed until the tumor length reached 5 mm.%ID/gmax was used to quantitate ER expression. ER expression was also detected by immunohistochemistry. Results：The tumor formation rates for ZR-75-1, MCF-7 and MDA-MB-231 were 100%（10/10）, 70%（7/10） and 100%（5/5）, respectively. There was no statistical difference in the volume among three groups （P〉0.05）.%ID/gmax values were 6.6±1.0, 3.3±0.5 and 1.1±0.1, respectively. Signiifcant differences were observed when ZR-75-1 was compared to MCF-7 （P〈0.05） and MDA-MB-231 （P﹤0.001）. There was signiifcant difference between MCF-7 and MDA-MB-231 （P〈0.05）. The ratios of tumor to muscle （T/M） were 4.2±0.3, 2.6±0.2 and 1.1±0.1, respectively. There were signiifcant differences among three groups （P﹤0.001）. A signiifcantly positive correlation was found between the results＆amp;nbsp;of 18F-FES imaging and immunohistochemistry （%ID/gmax：r2=0.65, P〈0.001;T/M：r2=0.87, P〈0.001）. Conclusion：%ID/gmax from 18F-FES PET/CT imaging is able to evaluate ER expression reliably. 18F-FES PET/CT can be used as a noninvasive and dynamic method in vivo.
出处
《肿瘤影像学》
2015年第1期35-40,共6页
Oncoradiology
基金
上海市科委项目(No:12431900208)
上海分子影像探针工程技术研究中心项目(14DZ2251400)
